SPECT/CT in Endocrine and Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management: Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up. It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Detailed Description
-----------------
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT). We hypothesize that NM -CT data has advantages over the data obtained using separately performed NM study and conventional anatomic imaging as CT. We hypothesize that more accurate localization of the radio-isotope activity on NM images will improve diagnostic accuracy and will have an impact on patient management: Improved accuracy of NM study will improve tumor localization, the evaluation of the extent of disease and the post therapy follow up. It will direct other diagnostic procedures to lesions otherwise undetected, or exclude the need for more invasive procedures. It can also guide invasive procedures and radiation-therapy planning, thus improving therapy results and avoiding unnecessary treatment-related side effects.

Official Title
-----------------
The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors

Conditions
-----------------
Endocrine and Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Device: SPECT/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient referred for NM scintigraphy to assess the presence of endocrine or neuroendocrine tumors. Patient signed informed consent Exclusion Criteria: The study will not be performed in pregnant or lactating women. Patient will not be able or willing to tolerate the scan until its completion.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SPECT/CT|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The impact of imaging modality on patient management |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The impact of imaging modality on patient management |  |  |